EGLE Therapeutics adds John Celebi to its Board as Independent Director

– FRANCE, Paris –  EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, today announced the appointment of John Celebi to its Board as an Independent Director.

The company also announced the appointment of Dr. Pejvack Motlagh (MD, MSc) as CMO.

“We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity. Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells,” said Interim CEO Dr. Vincent Brichard.

About John Celebi

John Celebi brings over 25 years of experience building innovative entrepreneurial biotechnology companies. He currently serves as President and CEO of Sensei Biotherapeutics (NASDAQ: SNSE), a biotechnology company focused on the discovery and development of novel immunotherapies for cancer patients with unmet needs. Previously, John Celebi served as COO of X4 Pharmaceuticals where he established and oversaw the company’s oncology business strategy. He also served as CBO of Igenica Biotherapeutics, Inc., an immunotherapy company formed by The Column Group, 5 AM Ventures, Orbimed, and Third Rock Ventures, where he established key academic and industry relationships, including with MedImmune. Mr. Celebi has extensive transactional and alliance management experience, having served as VP of Business Development, New Product Planning, and Alliance Management at ArQule, Inc., where he played a central role in the formation of alliances with Roche, Daiichi-Sankyo, and Kyowa Hakko Kirin. Mr. Celebi was an early employee at Tularik, Inc., where he conducted drug discovery and basic research.

“This is a transformational period for Egle Therapeutics as the company further strengthens its team and advances toward the clinic a series of highly novel candidates aimed at arming or disarming Treg function to achieve the desired therapeutic outcome. I look forward to collaborating with this talented Board and management team as we advance Egle’s compelling pipeline for patients with unmet need,” said John Celebi.

John Celebi received an MBA from Carnegie Mellon University and a B.S. in biophysics from the University of California, San Diego.

About Dr. Pejvack Motlagh

Dr. Pejvack Motlagh a seasoned clinical development executive who has previously held overall responsibility for candidate development from first in human through registrational studies, brings to Egle Therapeutics the appropriate expertise and successful drug development experience. As CMO, he will be responsible for advancing Egle’s pipeline towards the clinic and notably EGL-001 (a Treg-selective anti-CTLA4-IL-2m) in oncology and EGL-003 (a non-targeted IL-2 Treg engager) in auto-immune diseases. Before Egle Therapeutics, Dr. Motlagh was CMO at Mablink, an ADC biotech company, where through the establishment of a differentiating clinical development plan he contributed to the value creation leading to an acquisition by Eli Lilly. Previously, he held global positions at leading oncology companies such as GSK, Bristol-Myers Squibb, and AstraZeneca, where he was instrumental in the transition of several compounds toward the late clinical development phases of now-approved drugs. At Boehringer Ingelheim, he oversaw, managed, and prioritized their whole IO portfolio.

About Egle Therapeutics SAS

Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg-specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently developed in IND-enabling studies.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.